Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy by unknown
Tomioka et al. BMC Cancer  (2015) 15:420 
DOI 10.1186/s12885-015-1429-0RESEARCH ARTICLE Open AccessRisk factors of PSA progression and overall
survival in patients with localized and locally
advanced prostate cancer treated with primary
androgen deprivation therapy
Atsushi Tomioka, Nobumichi Tanaka, Motokiyo Yoshikawa, Makito Miyake, Satoshi Anai, Yoshitomo Chihara,
Eijiro Okajima, Akihide Hirayama, Yoshihiko Hirao and Kiyohide Fujimoto*Abstract
Background: Primary androgen deprivation therapy (PADT) has played an important role in the treatment of
prostate cancer. We sought to identify factors of PSA progression in our series of patients with localized and locally
advanced prostate cancer treated with PADT.
Methods: Six-hundred forty-nine patients with localized and locally advanced prostate cancer who received PADT
from 1998 to 2005 by Nara Uro-Oncology Research Group were enrolled. Age, T classification, stage, PSA level at
diagnosis, Gleason score, laterality of cancer detected by biopsy and seminal vesicle involvement (SVI) were adopted
as parameters of PSA progression. Cox’s proportional hazards model was used to determine the predictive factors
for PSA progression.
Results: The median follow-up period and the median PSA level at diagnosis were 49 months and 15 ng/mL. The
5-year disease specific survival rate, overall survival rate and PSA progression-free survival (PFS) rate were 97.9 %,
91.9 % and 71.2 %, respectively. The univariate analysis showed that the PSA level at diagnosis, Gleason score,
laterality of cancer detected by biopsy and SVI were independent predictive parameters of PSA-PFS. However, by
multivariate analysis, only laterality of cancer detected by biopsy (unilateral vs. bilateral) was an independent predictive
parameter of PSA-PFS (p = 0.034). The patients were classified into new risk groups base on three factors: PSA level at
diagnosis, Gleason score, and laterality of cancer detected by biopsy. The PSA-PFS rates at 5-years in the low- (none or
one factor), intermediate- (two factors) and high-risk (three factors) groups were 78.2 %, 62.5 % and 46.9 % (p < 0.001),
respectively.
Conclusion: In localized or locally advanced prostate cancer patients who received PADT, laterality of cancer detected
by biopsy was a significant predictor associated with a longer PSA-PFS. Our new risk grouping indicates the usefulness
of PSA-PFS.
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Androgen deprivation therapy (ADT) has played an im-
portant role in the treatment of prostate cancer since it
was first reported by Huggins and Hodges [1]. Initially,
ADT consisted of either surgical castration or estrogen ad-
ministration. However, these procedures have problems* Correspondence: kiyokun@naramed-u.ac.jp
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shown to facilitate stronger androgen suppression.
Widespread screening for prostate-specific antigen
(PSA) has led to a significant increase in the detection of
early stage, clinically localized prostate cancer. Currently,
treatment of localized prostate cancer remains contro-
versial. In the US it is frowned upon to give ADT for lo-
calized disease. The CaPSURE data from the USA
indicated that 44 % of patients underwent radical prosta-
tectomy, 23 % received definitive radiotherapy and 20 %
received primary androgen deprivation therapy (PADT)
[2]. On the other hand, the Japan Prostate Cancer Study
Group showed the corresponding figures were 39.5 %,
23.9 % and 28.0 %, respectively [3] and the figures from
Nara Uro-Oncological Research Group (NUORG) were
40 %, 16 % and 38 %, respectively [4–6]. As background
of the present study, several reasons why Japanese pa-
tients with localized and locally advanced prostate can-
cer hesitate to undergo radical prostatectomy and prefer
to receive PADT are proposed. Firstly, all patients are
completely covered by the public health insurance sys-
tem in Japan [5]. Secondly, Japanese patients tolerate
hormonal therapy well without severe side effects for a
long time [7, 8]. Thirdly, in those days radiotherapy was
not widespread and doctors at hospitals where modal-
ities for radiation therapy were not available usually
chose PADT if the patients were unwilling to undergo
radical prostatectomy [4, 5]. Fourthly, in those days,
49.9 % of the patients with localized or locally advanced
prostate cancer were considered as the D’Amico high-
risk group. 5-year biochemical recurrence-free rate in
the D’Amico high-risk group treated with prostatectomy
estimated 46.3 % [9]. 51 % of the patients with localized
or locally advanced prostate cancer received PADT [4].
Recently, ADT is used as the primary treatment for ad-
vanced prostate cancer, and the efficacy of PADT for local-
ized or locally advanced prostate cancer has also been
reported [10, 11]. Mounting data on the efficacy and safety
of ADT has brought about increased use of PADT in pa-
tients with localized or locally advanced prostate cancer in
many countries, despite limited evidence to date on the
impact on clinical outcomes [12–14].
We performed a retrospective study of the efficacy of
PADT and identified risk factors for PSA progression in
our series of patients with localized and locally advanced
prostate cancer.
Methods
This study retrospectively evaluated 649 Japanese pa-
tients with localized and locally advanced prostate can-
cer who received PADT following diagnosis by the
NUORG between January 1998 and December 2005.
The diagnosis was based on prostate biopsy. Computed
tomography, bone scans, magnetic resonance imagingand/or transrectal ultrasonography were used in all
cases. These patients selected PADT for various reasons,
including older age, patient’s preference and comorbidity
such as severe cardiovascular disease or other malignan-
cies, although definitive therapy such as radical prosta-
tectomy or irradiation is the standard treatment for
patients with localized prostate cancer.
Follow-up data were retrieved from hospital medical
records. Patients were followed every month for the first
3 months and every 3 months thereafter. PSA progres-
sion was defined as the first day when the PSA was in-
creased for three consecutive times or when clear
clinical radiological evidence of progressive disease was
seen. PSA progression-free survival (PFS) rate was esti-
mated by the Kaplan-Meier method and the log rank
test was used to assess differences between groups: Age
(≤75 vs. 76≤), T classification, stage (B vs. C), PSA level
at diagnosis (<10 ng/mL vs. 10–20 ng/mL vs. 20 ng/
mL≤), Gleason score (6 vs. 7 vs. 8≤), laterality of cancer
detected by biopsy (unilateral vs. bilateral) and seminal
vesicle involvement (SVI; negative vs. positive). Based on
the result of the log rank test, the Cox proportional haz-
ards regression model was performed to analyze inde-
pendent predictors of PSA progression.
We classified the patients into the modified D’Amico
risk groups [15] and the Japan Cancer of the prostate Risk
Assessment (J-CAPRA) risk groups [16]. The modified
D’Amico risk grouping classifies patients into three risk
groups based on PSA level at diagnosis and Gleason score:
low- (PSA level at diagnosis ≤10 ng/mL and Gleason
score ≤ 6; 112 patients), intermediate- (10 ng/mL < PSA
level at diagnosis ≤20 ng/mL and/or Gleason score 7; 203
patients), and high- risk (PSA level at diagnosis >20 ng/
mL or 8 ≤Gleason score; 334 patients). In J-CAPRA risk
grouping, patients were assigned 1 point for Gleason score
7 and 2 points for Gleason score 8 to 10; 1 point for PSA
level at diagnosis 20 to 100 ng/mL, 2 points for PSA 100
to 500 ng/mL, and 3 points for PSA higher than 500 ng/
mL; 1 point for stage T2c or T3a, 2 points for T3b, and 3
points for T4. Points for each variable are summed to
yield a total score with a range of 0 to 12. The J-CAPRA
score was also categorized to identify three groups at low-
(0 to 2 points; 459 patients), intermediate- (3 to 7 points;
190 patients) and high- (8 to 12 points; 0 patient) risk of
recurrence.
Statistical analysis was performed SPSS 11.0 J (SPSS
Inc., Chicago, Illinois) and p < 0.05 was considered statisti-
cally significant. The product limit method of Kaplan-
Meier was used to assess survival. The log-rank method
was used to assess differences between groups. The Cox
proportional hazards model was performed to analyze
independent predictors of PSA-PFS. Only the variables
that were found to be significant in the univariate ana-
lyses (p < 0.05) were entered into the multivariate
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predicting disease outcome.
The Medical Ethics Committee of Nara Medical Uni-
versity approved this retrospective study.Results
The median age, the median follow-up period and the me-
dian PSA level at diagnosis were 77 years (mean: 76.5;
range: 53–95), 49 months (mean: 52.0; range: 12–143) and
15 ng/mL (mean: 28.9; range: 1.4 – 200), respectively
(Table 1). The number of patient cores was varied and the
median was 7 (mean: 8.03; range: 2–25). The 5-year over-
all survival rate was 91.9 % and 7.6 % of patients (49 pa-
tients) died during follow-up. The 5-year disease specific
survival rate was 97.9 % and 1.2 % of patients (8 patients)
died of prostate cancer (Fig. 1). The 5-year PSA-PFS rates
were 71.2 % (Fig. 2). A total of 566 patients (87.2 %), 70
patients (10.8 %) and 13 patients (2.0 %) were treated with
CAB, LH-RH agonist alone and anti-androgen alone, re-
spectively. Significant differences in a log-rank test of
PSA-PFS rates was observed between CAB and LH-RH
agonist alone (p = 0.015) (Fig. 3).
Table 2 shows the results of analysis for PSA-PFS by a
log-rank test. T classification (T1c vs.T2c; p = 0.036, T1c
vs.T3b; p = 0.028, T2ab vs.T2c; p = 0.001, T2ab vs. T3b;
p = 0.003), PSA level at diagnosis (10–20 ng/mL vs.
20 ng/mL≤; p = 0.002, <10 ng/mL vs. 20 ng/mL≤; p <
0.001), Gleason score (7 vs. 8≤; p = 0.028, 6 vs. 8≤; p =
0.004), laterality of cancer detected by biopsy (unilateral
vs. bilateral; p < 0.001) and SVI (negative vs. positive;
p = 0.030) were significantly associated with PSA-PFS.
We used a Cox’s proportional hazards model to deter-
mine the predictive parameter of PSA progression. Based
on the result of the log-rank test, age (≤75 vs. 76≤), stage
(B vs. C), PSA level at diagnosis (<20 ng/mL vs. 20 ng/
mL≤), Gleason score (≤7 vs. 8≤), laterality of cancer de-
tected by biopsy (unilateral vs. bilateral) and SVI (nega-
tive vs. positive) were adopted as clinicopathological
parameters of PSA progression and T classification was
excluded as a parameter in grouping the patients, be-
cause it was difficult to distinguish the cutoff point. PSA
level at diagnosis, Gleason score, laterality of cancer de-
tected by biopsy and SVI were the significant factors
for a longer PSA-PFS. But, by multivariate analysis,
only laterality of cancer detected by biopsy was an inde-
pendent predictive parameter of PSA-PFS (HazardTable 1 Characteristic of patients
Median Mean Range
Age (years) 77 76.5 53-95
Follow-up period (months) 49 52.0 12-143
PSA level at diagnosis (ng/mL) 15 28.9 1.4-200ratio: 1.523, p = 0.034, 95 % confidence interval: 1.033-
2.245) (Table 3).
PSA-PFS rates at 5 years in low-, intermediate- and
high-risk groups by the modified D’Amico risk grouping
were 80.7 %, 78.5 % and 63.8 % (Fig. 4). A significant dif-
ference in PSA-PFS rate was observed between the
intermediate- and high-risk groups (p = 0.003), but there
was no difference between the low- and intermediate-
risk groups (p = 0.493), as reported by Ueno et al. [14].
In the J-CAPRA risk grouping, PSA-PFS rates at 5 years
in the low- and intermediate- risk groups were 78.3 %
and 49.9 % (p < 0.001) (Fig. 5).
We classified the patients into our new risk groups
based on three factors: PSA level at diagnosis (<20 ng/mL
vs. 20 ng/mL≤), Gleason score (≤7 vs. 8≤) and laterality of
cancer detected by biopsy (unilateral vs. bilateral). The
low- (431 patients), intermediate- (153 patients) and high-
risk (65 patients) groups included none or one, two and
three factors, respectively. PSA-PFS rates at 5 years in the
respective risk groups were 78.2 %, 62.5 % and 46.9 %, re-
spectively, and a significant difference in the PSA-PFS rate
was observed between groups by the log-rank test (p <
0.001) (Fig. 6). The Cox proportional hazards model
showed the same result as the log-rank test (Table 4).
Discussion
Although PADT has been widely used for the treatment
of prostate cancer at any early disease stage, there is not
much information regarding the clinical outcomes associ-
ated with clinically localized and locally advanced prostate
cancer treated by PADT. According to some reports, a
survival advantage of CAB over castration monotherapy
has been indicated [10, 16, 17]. Thus, the focus of the
present study was placed on CAB rather than castration
monotherapy as PADT to evaluate its efficacy in terms of
long-term disease control of clinically localized and locally
advanced prostate cancer.
At the present time, the younger patients with local-
ized prostate cancer and locally advanced prostate can-
cer without complications have a tendency to select the
radical treatment such as prostatectomy. But, in those
days, the use of PADT was still common in patients with
localized prostate cancer and locally advanced prostate
cancer in Japan [4, 6]. In many cases, the patients might
select PADT by older age or some complications.
In this study, the PSA-PFS (71.2 % at 5 years) was
similar to other previous reports [10, 16–18]. These re-
sults were worse than other treatment modalities such
as prostatectomy and radiotherapy. If the PSA progres-
sion was defined as the day when the PSA at least
4 weeks later was 25 % increase over nadir with more
than 2 ng/mL, the PSA-PFS might be better. The disease
specific survival rate was very high (97.9 % at 5 years)

















































Fig. 1 Kaplan-Meier plots showing the incidence of disease specific and overall survival rate
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cancer by PADT. Egawa et al. reported that PADT was
as effective as radical prostatectomy with regard to
disease-specific survival rate in localized prostate cancer
[19] and Akaza et al. demonstrated no difference in
overall survival in patients with localized prostate cancer
treated with PADT and men of the same age among the
general population, suggesting that there is no increase
in the mortality of men treated with PADT [7].
Although prospective data defining the risks and bene-
fits are lacking, clinical practice trends show an in-
creased use of ADT as monotherapy. Date from theFig. 2 Kaplan-Meier plot showing the incidence of PSA progression-free suresults of the CAPSURE™ survey shows an increase in
the incidence of patients treated with PADT from 1989
to 2000, during which time the percent assigned to the
low-, intermediate- and high-risk groups increased from
4.6 % to 14.2 %, 8.9 % to 19.7 % and 32.8 % to 48.2 %, re-
spectively [20].
On the other hand, there is growing evidence that
ADT is associated with an increased risk of various co-
morbidities including ischemic heart disease, metabolic
syndrome, glucose intolerance, and a decrease in bone
mineral density [21–24]. As a result, patients who re-
ceived PADT have worse overall survival compared withrvival rate
Fig. 3 Kaplan-Meier plots showing the incidence of PSA progression-free survival rate classified by treatment
Table 2 Results of analysis of PSA-PFS by log-rank test
No. of patients No. of PSA progression 5 year PSA-PFS rate log-Rank
Total 649 161 71.2 %
Age ≤75 265 66 73.9 %
76≤ 384 95 69.0 % 0.230
T classification T1c 189 42 71.8 %
T2ab 205 37 78.9 %
T2c 104 36 65.2 % *
T3a 103 28 70.1 %
T3b 48 18 54.0 %
Stage B 498 115 73.2 %
C 151 46 64.9 % 0.155
PSA level at diagnosis <10 197 31 83.2 %
10-20 195 42 75.2 % **
20≤ 257 88 59.4 %
Gleason score 6 288 60 76.2 %
7 196 43 72.0 % ***
8≤ 165 58 61.8 %
Laterality of cancer detected by biopsy Unilateral 365 66 77.2 %
Bilateral 284 95 63.8 % <0.001
SVI Negative 601 143 72.7 %
Positive 48 18 54.0 % 0.030
PSA-PFS: PSA progression-free survival
SVI: seminal vesicle involvement
*: T1c vs. T2c; p = 0.036. T1c vs. T3b; p = 0.028. T2ab vs. T2c; p = 0.001. T2ab vs. T3b; p = 0.003. others; p > 0.05
**: <10 vs. 10–20; p = 0.192. 10–20 vs. 20≤; p = 0.002. <10 vs. 20≤; p < 0.001
***: 6 vs. 7, p = 0.310. 7 vs. 8≤; p = 0.028. 6 vs. 8≤; p = 0.004
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Table 3 Results of analysis of PSA-PFS by Cox proportional hazards model
Univariate Multivariate
Hazard-ratio p 95 % CI Hazard-ratio p 95 % CI
Age ≤75 1
76≤ 1.213 0.232 0.884- 1.666
Stage B 1
C 1.283 0.157 0.908-1.813
PSA level at diagnosis <20 1 1
20≤ 2.048 <0.001 1.500-2.797 1.613 0.071 0.959-2.711
Gleason score ≤7 1 1
8≤ 1.734 0.001 1.256-2.393 1.436 0.064 0.979-2.107
Laterality of cancer detected by biopsy unilateral 1 1
bilateral 2.102 <0.001 1.533- 2.883 1.523 0.034 1.033-2.245
SVI Negative 1 1
Positive 1.71 0.032 1.046- 2.793 1.109 0.753 0.582-2.113
PSA-PFS: PSA progression-free survival
95 % CI: 95 % confidence interval
SVI: seminal vesicle involvement
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reports have also shown no significant increase in car-
diovascular mortality with ADT in men with prostate
cancer [27–29].
Several parameters were isolated as predictors of PSA
progression. Nadir PSA level and the percentage ofFig. 4 Kaplan-Meier plots showing the incidence of PSA progression-free spositive biopsy cores remained as independent prognos-
tic factors on multivariate analysis [18]. Younger patients
(<70 years) and those with 6 ≤Gleason score were at a
higher risk of treatment failure [30]. Ueno et al. reported
that PSA ≤20 ng/mL, Gleason score ≤7, and time to
nadir PSA ≤6 months showed a good response to PADTurvival rate classified by D’Amico risk grouping
Fig. 5 Kaplan-Meier plots showing the incidence of PSA progression-free survival rate classified by J-CAPRA risk grouping
Tomioka et al. BMC Cancer  (2015) 15:420 Page 7 of 9[17]. In this study, there was no difference between Gleason
score of 6 vs. 7 ≤ (p = 0.310), and we adopted a Gleason score
≤7 vs. 8 ≤ as a parameter of PSA progression in Cox’s pro-
portional hazards model. We found that PSA level at diagno-
sis, Gleason score, laterality of cancer detected by biopsy and
SVI were significant factors for a longer PSA-PFS, except forFig. 6 Kaplan-Meier plots showing the incidence of PSA progression-free sage and stage by univariate analysis. Then, by multivariate
analysis, only laterality of the cancer detected by biopsy was
an independent predictive parameter of PSA-PFS.
Firstly, we classified the patients using our four new
risk groups: no, one, two and three factors. No signifi-
cance difference was shown between the no factorurvival rate classified by our new risk grouping
Table 4 The Cox proportional hazards model of PSA-PFS
Hazard-ratio p 95 % CI
D’Amico Low 1
Intermediate 1.212 0.493 0.693-2.119
High 2.116 0.003 1.289-3.492
J-CAPRA Low 1
Intermediate 2.623 <0.001 1.942-3.542
Our new grouping Low 1
Intermediate 1.936 <0.001 1.350-2.778
High 3.408 <0.001 2.269-5.117
PSA-PFS: PSA progression-free survival
95 % CI: 95 % confidence interval
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209 of 649 patients) (p = 0.091). Therefore we com-
bined the no and one factor into the low-risk group.
Our low-risk factor patients accounted for two-thirds of
the T1c-T3b patients. For patients showing a good re-
sponse to ADT, ADT showed an excellent effect in this
study. This effect may be explained by the observation
that resected specimens after neoadjuvant ADT were
sometimes completely apoptotic. Kitagawa et al. analyzed
the histological effects of ADT in specimens from patients
treated with radical prostatectomy after neoadjuvant ADT
[31]. They reported that histologically cured or nearly
cured patients accounted for more than 40 % of the total
number. In addition, the recurrence-free survival rate of
patients with complete apoptosis was 100 %. These results
supported our observation that some cases of localized
prostate cancer could be cured by ADT alone. Schulman
et al. also performed neoadjuvant ADT for 3 months be-
fore radical prostatectomy in patients with localized pros-
tate cancer, and good histopathological effects [32].
In the modified D’Amico risk grouping, a significant
difference in PSA-PFS rate was observed between the
intermediate- and high-risk groups, but there was no
difference between the low- and intermediate-risk
groups. The J-CAPRA risk grouping included also
metastatic cancer patients in addition to localized and
locally advanced prostate cancer. Our new risk groups
included only localized and locally advanced prostate
cancer patients and a significant difference of PSA-PFS
rate was observed between all groups. Our new risk
grouping indicates the usefulness for localized and lo-
cally advanced prostate cancer patients treated with
PADT.
There are several limitations to the current study.
Firstly, there may be interobserver variation of the Glea-
son score between general pathologists and uropatholo-
gists. Secondly, the current study is retrospective and
results should be interpreted accordingly.Conclusions
Unilateral positive biopsy was a significant predictor associ-
ated with a longer PSA-PFS in localized or locally advanced
prostate cancer patients who received PADT. Our new risk
groups according to the three factors of PSA level at diag-
nosis, Gleason score and laterality of cancer detected by bi-
opsy indicate the usefulness for PSA-PFS. The efficacy and
toxicity of ADT for localized or locally advanced prostate
cancer requires further study before it can be recom-
mended as the primary treatment. In the future, a pro-
spective randomized study or comparative study of QOL
or medical cost compared with other treatments will be
necessary to establish PADT as a recommended treatment
for early prostate cancer. Our results provide potentially
clinical useful predictive tools for physicians and patients
contemplating PADT for localized or locally advanced
prostate cancer as well as the outcomes necessary to de-
sign prospective studies of the treatment strategy.
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